Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders
Authors:
- Eirik KjelbyEKEirik Kjelby
- Rolf Dr Philos GjestadRGRolf Dr Philos Gjestad
- Farivar FathianFFFarivar Fathian
- Igne SinkeviciuteISIgne Sinkeviciute
- Renata AlisauskieneRARenata Alisauskiene
- Liss AndaLALiss Anda
- Else-Marie LøbergELElse-Marie Løberg
- Solveig Klæbo ReitanSRSolveig Klæbo Reitan
- Inge JoaIJInge Joa
- Tor Ketil LarsenTLTor Ketil Larsen
- Maria RettenbacherMRMaria Rettenbacher
- Jan Øystein BerleJBJan Øystein Berle
Open Access
- 1 May 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (3) , 246-258
Abstract
Background: Depressive symptoms are frequent in schizophrenia and associated with a poorer outcome. Currently, the optimal treatment for depressive symptoms in schizophrenia remains undetermined. Amisulpride, aripiprazole, and olanzapine all have antidepressive pharmacodynamic properties, ranging from serotonergic affinities to limbic dopaminergic selectivity. Consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the Calgary Depression Scale for Schizophrenia sum score in patients within the schizophrenia spectrum. Methods: Psychotic patients within the schizophrenia spectrum were included, and effectiveness was analyzed with latent growth curve modeling. Results: Of the 144 patients, 51 (35%) were women, the mean age was 31.7 (SD 12.7), and 39% were antipsychotic naive. At inclusion, 68 (47%) participants had a Calgary Depression Scale for Schizophrenia sum score >6, indicating severe depressive symptoms. Across the 12-month follow-up, there was a depressive symptom reduction in all medication groups, but no statistically significant differences between the study drugs. Separate analyses of the subcohort with elevated depressive symptoms at inclusion also failed to find differences in depressive symptom reduction between study drugs. The reduction in depressive symptoms mainly occurred within 6 weeks after randomization. Conclusions: There was a reduction in depressive symptoms under treatment with amisulpride, aripiprazole, and olanzapine in acutely psychotic patients with schizophrenia spectrum disorder, but no differences between the drugs.Keywords
This publication has 81 references indexed in Scilit:
- Clinical characteristics in schizophrenia patients with or without suicide attempts and non-suicidal self-harm - a cross-sectional studyBMC Psychiatry, 2013
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trialBMC Psychiatry, 2011
- Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remissionSchizophrenia Research, 2009
- Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivoPsychopharmacology, 2009
- Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design FeaturesSchizophrenia Bulletin, 2008
- Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective DisorderThe Journal of Clinical Psychiatry, 2008
- Aripiprazole in the Treatment of Depressive and Anxiety DisordersCNS Drugs, 2008
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005
- Exercise as an adjunct treatment for schizophrenia: A review of the literatureJournal of Mental Health, 1999